NasdaqGS:SRPTBiotechs
ELEVIDYS Label Changes and Pipeline Progress Could Be a Game Changer for Sarepta Therapeutics (SRPT)
In November 2025, Sarepta Therapeutics announced progress in its Phase 1/2 clinical study of SRP-1003 for myotonic dystrophy, and provided updates to the prescribing information for ELEVIDYS, its approved gene therapy for Duchenne muscular dystrophy, including a new boxed warning for acute liver risks and label changes affecting patient eligibility.
The updates also trigger a milestone payment of US$200 million to Arrowhead Pharmaceuticals and highlight ongoing collaboration efforts to...